-
Mashup Score: 1Cohorts - E2-RADIatE - 10 month(s) ago
Cohorts
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ReCare: first site active - E2-RADIatE - 11 month(s) ago
We are very happy to announce that the first site for ReCare has been activated. ReCare is a cohort of the E2-RADIatE platform that focuses on…
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We are delighted to announce that the first site for #ReCare, a cohort of the #E2RADIatE platform, has been activated. More: https://t.co/rFtnk9wBif @WBA_Global, @NAndratschke, @jonas_willmann, Nieder Carsten, #CancerResearch #ClinicalTrials #Oncology https://t.co/cfqF1M8KZf
-
-
Mashup Score: 1OligoCare: 2000 patients enrolled - 1 year(s) ago
OligoCare: 2000 patients enrolled We are delighted to announce that on the 11th of April 2023, the RP-1822 OligoCare cohort of the 1811-E²-RADIatE platform successfully enrolled its 2000th patient, marking a significant milestone for the cohort initiated in 2019.
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Delighted to announce that the #E2RADIatE platform’s #OligoCare cohort has successfully enrolled its 2000th patient. More: https://t.co/f7KE7Nsq2W @WBA_Global @umbertoricardi, @MartaScorsetti, @alongi_filippo #CancerResearch #ClinicalTrials #Oncology https://t.co/7hdx6bB65b
-
-
Mashup Score: 0Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy - 1 year(s) ago
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite…
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Have you read our latest publication in collaboration with @ESTRO_RT on @TheLancetOncol about the impact of radical radiotherapy on patients with oligometastatic disease? Find out more: https://t.co/uAVNEH9gsU @piet_ost #OligoCare #E2RADIatE #CancerResearch #ClinicalTrials https://t.co/n6fA4A3bOx
-
-
Mashup Score: 0ESTRO and EORTC consensus on re-irradiation - 1 year(s) ago
ESTRO and EORTC consensus on re-irradiation Re-irradiation can be considered for local recurrence or new tumours adjacent to a previously irradiated site to achieve durable local control for patients with cancer who have otherwise few therapeutic options. With the use of new radiotherapy techniques, which allow for conformal treatment plans, image guidance,
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Excited to announce a new publication on @TheLancetOncol about @ESTRO_RT and @EORTC's consensus on re-irradiation. 📚Find out more: https://t.co/N0EwHwgl6x @WBA_Global #ClinicalCancerResearch #Radiotherapy
-
-
Mashup Score: 0OligoCare recruitment update - 1 year(s) ago
OligoCare recruitment update The OligoCare cohort of E²-RADIatE continues to recruit very well with a total of 1747 patients enrolled (cut-off 01st December 2022) at 45 institutions across Austria, Belgium, Czech Republic, France, Germany, Switzerland, Italy, Netherlands, Spain, Slovenia and the United Kingdom. The average accrual in 2022 is 58 patients enrolled per
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Happy to announce that in November, our sites achieved the second-best monthly accrual for #Oligocare (1822-RP), with 81 patients enrolled! Thanks to all patients and investigators! Find out more: https://t.co/thntwIhrOv @Mat_Guc @piet_ost @ESTRO_RT #SBRT #E2RADIatE https://t.co/jHVAQZX27t
-
-
Mashup Score: 0Homepage - 2 year(s) ago
E²-RADIatE THE PLATFORM FOR RADIOTHERAPY E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO), it aims to be a pan-European infrastructure and a
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Happy to announce that Ospedale Sacro Cuore Don Calabria in Negrar enrolled 200 patients in the OligoCare cohort of #E2RADIatE. Thanks to the team and all patients! @alongi_filippo, @mat_guc @piet_ost @ESTRO_RT 👉 https://t.co/4jAAmOS1QF #SBRT #CancerResearch #ClinicalTrials https://t.co/IKnpZBbVOB
-
-
Mashup Score: 1Homepage - 2 year(s) ago
E²-RADIatE THE PLATFORM FOR RADIOTHERAPY E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO), it aims to be a pan-European infrastructure and a
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We congratulate top recruiter @MartaScorsetti at @HumanitasMilano for enrolling 200 patients in the OligoCare cohort of #E2RADIatE. Thank you to the team and all patients! @Mat_Guc @piet_ost. @ESTRO_RT Find out more: https://t.co/4jAAmP9CId #SBRT #CancerResearch #ClinicalTrials https://t.co/oRIHmR2zj6
-
-
Mashup Score: 6Homepage - 2 year(s) ago
E²-RADIatE THE PLATFORM FOR RADIOTHERAPY E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO), it aims to be a pan-European infrastructure and a
Source: E2-RADIatECategories: Latest Headlines, Oncologists2Tweet-
Interested in enrolling in OligoCare: the registry for MDT for oligometastatic disease. Please go to https://t.co/N7nHzGgg4d @BertrandTOMBAL @Silke_Gillessen @APCCC_Lugano #APCCC22
-
RT @piet_ost: Interested in enrolling in OligoCare: the registry for MDT for oligometastatic disease. Please go to https://t.co/N7nHzGgg4d…
-
-
Mashup Score: 0Homepage - 3 year(s) ago
E²-RADIatE THE PLATFORM FOR RADIOTHERAPY E²-RADIatE (EORTC 1811 study) is a platform that collects real-world data through prospective data registries in radiotherapy. A collaboration between the European Organisation for Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO), it aims to be a pan-European infrastructure and a
Source: E2-RADIatECategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New #milestone: 500 patients enrolled for #OligoCare More information about this registry project for patients with oligometastatic disease: https://t.co/2ZnEZJIGOb #radonc #CancerResearch @piet_ost @Mat_Guc @ESTRO_RT https://t.co/MjByCsiF7m
-
📣 We are proud to announce that the first patient has been enrolled in the #ReCare Cohort of the #E2RADIatE platform. Learn more: https://t.co/GjrtqZEUsb @WBA_Global @NAndratschke @jonas_willmann Nieder Carsten #CancerResearch #ClinicalTrials #Oncology https://t.co/Hinp5X3Cgs